NBRV earnings

- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced it has pivoted its strategic focus towards commercialization efforts, primarily focused on SIVEXTRO, to extend its cash runway, while exploring strategic options. Nabriva also issued financial results for the t

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 833-634-2311 for domestic participants and 412-902-4177 for international p

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022. At the Annual General Meeting of Shareholders on August 11, 2022, Nabriva Therapeutics' shareholders approved, subject to and conditional upon the Board of Directors of Nabriva Therapeutics determining,

-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2022 and provided a corporate update. "We continued to accelerate our commercial growth through improved sales execution in the second quarter of 2022. We are seeing significant early success from our increased focus on SIVEXTRO

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. To participate in the conference call, please dial 833-634-2311 for domestic participants and 412-902-4177 for internation

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended March 31, 2022 and provided a corporate update. "We continued to execute on our near-term strategy in the first quarter

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 5, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 800-579-2543 for domestic participants and 203-518-9708 for international particip

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, March 29, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months and year ended December 31, 2021 and provided a corporate update. "We saw continued progress in our commercial business during the fourth quarter of 2021, w

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2021 financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, March 29, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 fo

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended September 30, 2021 and provided a corporate update. "We saw our commercial business continue to gain momentum in the third quarter, with total

DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Tuesday, November 9, 2021. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 for international participants, with Conferenc

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced its financial results for the three months ended June 30, 2021 and provided a corporate update. "We continued to bu

DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, August 5, 2021. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. The dial-in number for the conference call is 866-811-8671 for domestic participants and 409-981-0874 for international participants, with Conferenc